Both in the US (with Medicare/Medicaid) and China, the areas of medicine that see the most government spending on drugs also attract the most R&D investment. China strategically uses this mechanism to direct innovation towards its public health priorities.
The U.S. has made significant deregulatory changes, such as in stem cell research, but these are not widely known within the industry. This lack of awareness means companies are not taking advantage of new, more permissive pathways, slowing down potential innovation.
As it becomes easier and more efficient to run clinical trials in China, U.S. companies are increasingly outsourcing them. This creates a dependency where China could cut off access to trials or withhold critical new drugs, ceding the entire innovation edge.
Since 2016, China has rapidly reformed its systems, moving from a laggard to the global leader in initiating clinical trials. This lead extends beyond simple volume to pioneering completely new therapies, particularly in areas like cell and gene therapy.
The U.S. prohibits gene therapies that alter sperm or eggs, preventing hereditary changes. China's more permissive stance on this "germline editing" allows its researchers to pursue permanent cures for genetic diseases, giving them a significant lead in a revolutionary field.
The MAH system empowers drug developers to manage the entire process from preclinical data to manufacturing under a set of standards. Instead of continuous government inspections, a comprehensive audit occurs at the final stage, removing multiple stop-points and accelerating the approval process.
By enrolling more participants, Chinese clinical trials achieve greater statistical power. This reduces the likelihood of both Type 1 (false positive) and Type 2 (false negative) errors, leading to more reliable data and a lower chance of abandoning a truly effective drug.
China's government negotiates lower drug prices but then ensures mass adoption, increasing total revenue for pharmaceutical firms. This "win-win" approach contrasts with Western negotiations that typically reduce firm profits, making China a more attractive market for innovation.
Unlike the U.S. system, which often requires separate ethics reviews for each trial location, China has adopted a "parallel ethics" model. If one site's ethics committee approves a trial, that approval extends to all other participating sites, drastically reducing administrative delays.